Notice NOT-GM-20-026 from the NIH Guide for Grants and Contracts

Notice NOT-TR-20-019 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-045 from the NIH Guide for Grants and Contracts

Notice NOT-MD-20-019 from the NIH Guide for Grants and Contracts

Notice NOT-TR-20-017 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-047 from the NIH Guide for Grants and Contracts

Notice NOT-TR-20-016 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-043 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-041 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-20-030 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the NCI invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors. This RFA supports research that requires the creation of a new prospective cohort study of cancer survivors that addresses a gap in knowledge pertaining to the health of cancer survivors. Proposals must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or other understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and include information from the following five domains: 1) disease characteristics (e.g., type, stage), 2) individual survivor characteristics (e.g., comorbidities, SES, social connections, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity) and 5) quality of life outcomes (health related quality of life). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3 Planning-Exploratory Phase focused on recruitment and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 will be proposed by the PI, with approval by NCI, and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated so that all aims will be completed in the UH3 phase.

Notice NOT-TR-20-020 from the NIH Guide for Grants and Contracts

Notice NOT-HG-20-035 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-046 from the NIH Guide for Grants and Contracts

Notice NOT-AG-20-025 from the NIH Guide for Grants and Contracts

Notice NOT-AG-20-024 from the NIH Guide for Grants and Contracts

Notice NOT-AG-20-023 from the NIH Guide for Grants and Contracts

Notice NOT-AA-20-005 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Full Stack Software Engineer Location: Cambridge, Cambridgeshire, England

Notice NOT-TR-20-013 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-090 from the NIH Guide for Grants and Contracts